The a-glucosidase inhibitors acarbose and miglitol have been successfully used to control postprandial hyperglycaemia in diabetics.
BAY g 5421 (acarbose) and BAY m 1099 (miglitol) are competitive inhibitors of small intestinal ct-glucosidase. Acarbose is a pseudotetrasaccharide and has been used in clinical trials with insulin dependent and non-insulin dependent diabetes to control hyperglycaemia, improve the diabetic metabolic condition, and, if possible, to reduce the insulin requirements.' 2 Miglitol is a new a-glucosidase inhibitor with the chemical structure of a 1-desoxynojirimycin. It has already been used in a few clinical trials in normal volunteers and diabetics.3 4 Though intestinal a-glucosidase inhibitors interfere with sucrose and starch digestion,5 glucose absorption is not affected. 6 (Fig 2) , there was a significant negative log-linear correlation between the two variables after acarbose (Y=5.92-0.013x, r=-0.91, T=-8.75, p<0.001), miglitol (Y=5.83-0 013x, r= -0-86, T=-6.68, p=0.001), and placebo (Y=5.33-0.009x, r=-0-91, T=-9-02, p<0.001). The slopes of the regression lines, as well as the 
